MEX3A promotes the proliferation, migration, and invasion of non-small-cell lung cancer by activating the MEK/ERK pathway.

• DOI: 10.21203/rs.2.24545/v1
• Publication Date: 2020-02-25T22:33:00Z
• Authors: Yao Zhang; Hongjiu Ren; Bo Zhang; Yitong Xu; Qingfu Zhang; Jun Jiang; Muli Wudu; Hongbo Su; Xizi Jiang; Zongang Liu; Zifang Zou; Xueshan Qiu

Abstract Background: Lung cancer is the second most prevalent type of worldwide; however, its death highest among all cancers. Previous studies have shown that MEX3A associated with Argonaute (Ago) and CDX2 proteins, which are important in tumor progression. High expression also known to negatively affect therapeutic impact radiotherapy chemotherapy. Therefore, we investigated role non-small cell lung (NSCLC).Methods: Tumor specimens were collected from 87 NSCLC patients who underwent surgical resection between 2014 2019 at Pathology Archive First Affiliated Hospital China Medical University, subsequently used for immunohistochemistry. lines normal bronchial epithelial HBE line study effects by utilizing MEX3A-siRNA, MEX3A-plasmids, ERK pathway inhibitor U0126. Western blotting, colony formation assays, MTT Transwell assays or without Matrigel performed explore on NSCLC.Results: protein was differentiation (P=0.044), size (P=0.020), lympth node status (P=0.001), p-TNM stage (P=0.009) preferentially expressed tissues. found be localized nucleus. The level tissue significantly higher than tissue. According our study, promote proliferation, migration, invasion NSCLC. In addition, regulated P-MEK, P-ERK, CyclinA2, CDK4, CDK6, RhoA MMP2. MEK U0126 reduced biological , suggesting increases carcinogenic activity cells through activation MEK/ERK signaling pathway.Conclusion: These results suggest an association unfavorable clinicopathological characteristics patients. And progression increasing proliferative metastatic potential upregulation pathway. We propose a candidate prognostic biomarker target